Liability to alcohol dependence (AD) is heritable, but little is known about its complex polygenic architecture or its genetic relationship with other disorders. To discover loci associated with AD and characterize the relationship between AD and other psychiatric and behavioral outcomes, we carried out the largest genome-wide association study to date of DSM-IV-diagnosed AD. Genome-wide data on 14,904 individuals with AD and 37,944 controls from 28 case-control and family-based studies were meta-analyzed, stratified by genetic ancestry (European, n = 46,568; African, n = 6,280). Independent, genome-wide significant effects of different ADH1B variants were identified in European (rs1229984; P = 9.8 × 10 ). Significant genetic correlations were observed with 17 phenotypes, including schizophrenia, attention deficit-hyperactivity disorder, depression, and use of cigarettes and cannabis. The genetic underpinnings of AD only partially overlap with those for alcohol consumption, underscoring the genetic distinction between pathological and nonpathological drinking behaviors.
. AD, as defined by the Fourth Edition of the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)
, is a serious psychiatric disorder characterized by tolerance, withdrawal, loss of control over drinking, and excessive alcohol consumption despite negative health and social consequences. Among alcohol drinkers, 12% meet criteria for DSM-IV AD during their lifetimes 3 . In the United States, only 25% of those with AD ever receive treatment 4 . AD is moderately heritable (49% by a recent meta-analysis) 5 and numerous genome-wide association studies (GWAS) have aimed to identify loci contributing to this genetic variance (see ref. 6 for a review). According to one study, common single-nucleotide polymorphisms (SNPs) are responsible for as much as 30% of the variance in AD 7 , but few have been identified to date. Variants in the genes responsible for alcohol metabolism, especially ADH1B and ALDH2, have been strongly implicated [8] [9] [10] [11] [12] [13] . The association between AD (and related drinking phenotypes) and rs1229984, a missense SNP (Arg48His) in ADH1B that affects the conversion of alcohol to acetaldehyde, represents one of the largest common-variant effect sizes observed in psychiatry, with the His48 allele accelerating ethanol metabolism and affording an approximately threefold reduction in likelihood of AD across numerous studies 8, 10 . Another functional polymorphism, rs671 in ALDH2 (Glu504Lys), strongly affects alcohol metabolism by blocking conversion of acetaldehyde to acetate and has an even stronger effect on risk for AD, but is rare except in some Asian populations 8, 12, 13 ADH1B and ALDH2 polymorphisms, however, only explain a small proportion of the heritable variation in AD in populations of European or African ancestry.
In this study, the Substance Use Disorders working group of the Psychiatric Genomics Consortium (PGC-SUD 14 ) compiled the largest numbers of carefully diagnosed alcohol-dependent individuals and alcohol-exposed controls to date, from both casecontrol and family studies. These included substantial numbers of people with European ancestry (EU, n = 46, 568, including 38, 686 unrelated individuals) and people with admixed African-American ancestry (AA, n = 6,280, including 5,799 unrelated individuals) subjects. AD diagnoses were derived from clinician ratings or semistructured interviews following DSM-IV 2 criteria. Each study was subjected to stringent quality control before conducting GWAS within each population of each study, followed by a genome-wide meta-analysis. We estimated the SNP-heritability (h 2 g ) of AD and examined the extent to which aggregate genetic variation in AD is related to traits from 45 other GWAS, including continuous measures of alcohol consumption. We also examined whether polygenic risk scores (PRS) derived from these analyses predicted alcohol dependence and related measures of problem drinking in three independent samples.
Results

GWAS meta-analyses.
The transancestral discovery meta-analysis of GWAS of AD in 28 cohorts (Table 1 and Supplementary  Table 1 ) identified a genome-wide significant (GWS; P < 5 × 10 -8 ) association in the ADH gene cluster on chromosome 4 ( Fig. 1 and Table 2 ). Examining this locus in each population (Fig. 2 ), rs1229984 in ADH1B was the strongest associated variant from the analysis in EU (z = -7.13, P = 9. 8 × 10 -13 ), while rs2066702, also in ADH1B, was the most significant variant in AA (z = -5.98, P = 2. 2 × 10 -9 ). Transancestral modeling reinforced the robust effects of rs1229984 and other ADH1B SNPs on liability to AD across inverse-variance weighted, random effects, and Bayesian models (Supplementary Fig. 1 and Supplementary Table 2) .
Clumping the ADH locus for linkage disequilibrium (LD; r 2 < 0.1 within 500 kb) suggested multiple independent signals in both populations, with the differing leading alleles reflecting different LD structures and allele frequencies in each population (Table 2 and Supplementary Fig. 2 ). Conditional analyses controlling for rs1229984 and rs2066702 had limited power, but results showed limited attenuation of effect sizes between marginal and conditional analyses, consistent with the existence of additional independent effects in the region (Supplementary Table 3 and Supplementary Fig. 3 ). Suggestive independent signals in the A full list of authors and affiliations appears at the end of the paper.
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; conditional z = 4.53, P = 5. 8 × 10 -6 ) and insertion rs112346244 (marginal odds ratio = 0.912, s.e. = 0.024, z = -3.81, P = 1. 4 × 10 -4 ; conditional odds ratio = 0.883, s.e. = 0.025, z = -5.05, P = 4. 5 × 10 -7 ; Supplementary Table 3 ). Several additional variants that were prioritized in the conditional analysis, while not significant, were in moderate to strong LD with rs698 (marginal odds ratio = 1.115, s.e. = 0.021, z = 5.19, P = 2. 1 × 10 -7 ; conditional odds ratio = 1.084, s.e. = 0.021, z = 3.78, P = 1.6 × 10 -4 ), a functional ADH1C variant with a role in AD 8, 11 . A single novel SNP on chromosome 3, rs7644567, also reached GWS in the meta-analysis (z = 5.68, P = 1.36 × 10 -8 ; Supplementary  Fig. 4 ). Potential biological associations with rs7644567, including chromatin contacts ( Supplementary Fig. 5 ) and cerebellar expression of RBMS3, are summarized in Supplementary Methods. However, rs7644567 did not replicate in two independent AA samples (YalePenn 2 and Collaborative Study on the Genetics of Alcoholism (COGA) African-American Family GWAS (AAfGWAS)) or the independent FINRISK cohort; all three replication cohorts estimated effects of the minor allele in the opposite direction of the discovery meta-analysis (Supplementary Table 4 ; see Supplementary Information). The SNP is also rare in most EU samples (minor allele frequency (MAF) < 0.01), with the current GWAS results primarily attributable to AA cohorts, along with the Finnish Twin cohort (FinnTwin) and the Finnish Nicotine Addiction Genetics Project (NAG-Fin). The EU cohorts in the discovery meta-analysis show no evidence of association of AD with the SNPs in strongest LD with rs7644567 in African (rs13098461; z = 0.27, P = 0.79) or Finnish (rs9854300; z = 0.10, P = 0.92) reference samples (Supplementary Methods). Based on the clear lack of replication, there is insufficient evidence to conclude that rs7644567 is associated with AD based on the current results.
There was limited genome-wide evidence for heterogeneity across all cohorts, within ancestry, between ancestries, or between study designs within ancestry . Evidence for inflation from population stratification or other confounding was also limited in the discovery meta-analysis (λ = 0.962; Supplementary Fig. 9 ) and within EU (λ = 1.053, LD score regression (LDSR) intercept = 1.018) and AA (λ = 1.007, LDSR intercept = 0.991-0.997; Supplementary Methods). Gene-level association testing with MAGMA 15 did not identify any additional significant genes in EU or AA (Supplementary Table 5 and Supplementary Methods), likely due to lack of power.
Heritability and genetic correlations. Liability-scale SNPheritability of AD was estimated at h 2 g = 0.090 (s.e. = 0.019, z = 4.80, P = 8.02 × 10 -7 ) in the meta-analysis of unrelated EU samples.
Exclusion of the ADH1B locus did not substantially modify this estimate (h 2 g = 0.089, s.e. = 0.0185). Nominally significant polygenic signal for the meta-analysis of unrelated AA individuals was observed based on LDSR with scores computed from 1000 Genomes Project African populations (z = 2.12, P = 0.017), but the quantitative estimate of h 2 g was unstable depending on the choice of reference panel, reflecting the challenge of correctly specifying LDSR and robustly modeling LD for the AA population (Supplementary Methods).
Significant genetic correlation with AD in EU was observed for 17 traits after correction for multiple testing (P < 1.11 × 10 -3 for 45 tested traits; Fig. 3 and Supplementary Table 6 ). The largest positive correlations were with smoking initiation (r g = 0.708, s.e. = 0.134, P = 1.3 × 10 -7 ) and lifetime cannabis initiation (r g = 0.793, s.e. = 0.217, P = 2.5 × 10 -4 ), as well as with other psychiatric disorders, especially schizophrenia (r g = 0.357, s.e. = 0.054, P = 3.2 × 10 -11 ), attention deficit-hyperactivity disorder (r g = 0.444, s.e. = 0.097, P = 4. 2 × 10 -6 ), and depression (r g = 0.561, s.e. = 0.085, P = 3. 5 × 10 -11 ). Educational attainment (r g = -0.468, s.e. = 0.066, P = 9.7 × 10 -13 ) and age at first birth (higher values indicate that participants were older when they had their first child; r g = -0.626, s.e. = 0.104, P = 2.0 × 10 -9
) showed significant inverse genetic correlation with AD, suggesting that liability to AD risk was genetically related to lower educational attainment and lower age at which the participant had his or her first child.
Unexpected patterns of genetic correlation were observed when comparisons were made to other alcohol-related measures, indicating that those measures reflect aspects of alcohol use that are genetically distinguishable. AD was genetically correlated with alcohol consumption in a meta-analysis of the Alcohol Genomewide Association (AlcGen) and Cohorts for Aging and Research in Genomic Epidemiology Plus (CHARGE+ ) consortia 16 (r g = 0.695, s.e. = 0.155, P = 6.9 × 10 -6
), but only modestly with alcohol consumption from the recent large UK Biobank analysis 17 (r g = 0.371, s.e. = 0.092, P = 5. 2 × 10 -5 ). No significant genetic correlation was observed between AD and a recent GWAS of the alcohol use disorders identification test (AUDIT) in a 23andMe cohort 18 (r g = 0.076, s.e. = 0.171, P = 0.656), perhaps due to the low levels of drinking and drinking-related problems in that population 18 . AD is, however, nominally genetically correlated with GWAS of delay discounting in the 23andMe sample 19 (r g = 0.487, s.e. = 0.178, P = 6.0 × 10 -3
).
Association with ADH1B expression. Based on the strong observed association with rs1229984 and rs2066702, we examined whether other variants affecting ADH1B expression (expression quantitative trait loci) were also associated with AD using GTEx v7 results (https://www.gtexportal.org/)
20
. Three variants, rs11939328 (EU, P = 0.78; AA P = 0.98; transancestral (trans), P = 0.78), rs10516440 (EU, P = 3.97 × 10 ), and rs7664780 (EU, P = 0.87; AA, P = 0.083; trans, P = 0.405), were selected after LD-informed clumping and the exclusion of variants in LD (r 2 > 0.1) with the GWS coding alleles rs1229984 and rs2066702. Of these, only rs10516440 (AD conditional analyses: EU, P = 1.34 × 10 -3
; AA, P = 0.013; trans, P = 7.44 × 10 ) was a significant multitissue expression quantitative trait locus in random effects analysis for ADH1B (fixed effects test statistic S FE = 319.4, heterogeneity test statistic S Het = 27.6, combined P = 1. 4 × 10 -76 ), ADH1A (S FE = 139.4, S Het = 6.6, combined P = 6. 72 × 10 -33 ), and ADH1C (S FE = 167.3, S Het = 8.9, combined P = 1. 9 × 10 -39 ). Rs10516440 is an LD proxy (r 2 > 0.9) of rs6827898 ( Table 2) in populations of European and African descent. These variants are both located in an intergenic region in the ADH gene cluster between ADH1C and ADH7. In line with the fact that the protective coding alleles are associated with increased activity of the enzyme encoded by ADH1B, the major allele rs10516440*A was associated with increased ADH1B expression and reduced AD risk. Results from the discovery metaanalysis of all cohorts (n case = 14,904; n control = 37,944) for association of genome-wide SNPs with AD under a fixed effects meta-analysis weighted by effective sample size. Dashed red reference line indicates GWS after correction for multiple testing (P < 5 × 10 -8 ).
Articles Nature NeuroscieNce Associations with other GWS loci. We examined results for the eight independent variants associated at GWS levels with alcohol consumption in the UK Biobank 17 (Supplementary Table 7 ). Among the UK Biobank findings, three of the four reported variants in the ADH region of chromosome 4 (rs145452708, a proxy for rs1229984 with D' = 1, rs29001570 and rs35081954) were associated in the present study with AD (P values ranging from 3.5 × 10 -5 to 2.3 × 10 -10 ) with sign-concordant effects; the remaining variant was excluded from our analysis due to MAF < 0.01. The UK Biobank lead variant in KLB, rs11940694, was nominally associated with AD (P = 0.0097), though this did not surpass multiple-testing correction for the eight GWS alcohol consumption loci. We saw little evidence (P > 0.2) for association of AD with the reported loci at GCKR and CADM2, which may be due to differences in power for the given effect size or because these genes exert an influence on liability to consume alcohol but not later problems. The locus on chromosome 18 showed limited regional association with AD, but the index variant was not present in our analysis because it no longer appears in the 1000 Genomes Project Phase 3 reference panel 21 .
Polygenic risk score analyses. PRS based on our meta-analysis of AD were significantly predictive of AD outcomes in all three tested external cohorts. PRS derived from the unrelated EU GWAS predicted up to 0.51% of the variance in past month alcohol use disorder in the Avon Longitudinal Study of Parents and Children (ALSPAC; P = 0.0195; Supplementary Fig. 10a ) and up to 0.3% of problem drinking in Generation Scotland (P = 7.9 × 10 -6 ; Supplementary  Fig. 10b ) as indexed by the CAGE (Cutting down, Annoyance by criticism, Guilty feelings, and Eye-openers) questionnaire. PRS derived from the unrelated AA GWAS predicted up to 1.7% of the variance in alcohol dependence in the COGA AAfGWAS cohort (P = 1.92 × 10 -7 ; Supplementary Fig. 10c ). Notably, PRS derived from the unrelated EU GWAS showed much weaker prediction (maximum r 2 = 0.37%, P = 0.01; Supplementary Fig. 10d ) in the COGA AAfGWAS than the ancestrally matched AA GWAS-based PRS despite the much smaller discovery sample for AA. In addition, the AA GWAS-based AD PRS also still yielded significant variance explained after controlling for other genetic factors (r 2 = 1.16%, P = 2.5 × 10 -7 ). Prediction of CAGE scores in Generation Scotland remained significant and showed minimal attenuation (r 2 = 0.29%, P = 1.0 × 10 -5 ) after conditioning on PRS for alcohol consumption derived from UK Biobank results 17 . In COGA AAfGWAS, the AA PRS derived from our study continued to predict 1.6% of the variance in alcohol dependence after inclusion of rs2066702 genotype as a covariate, indicating independent polygenic effects beyond the lead ADH1B variant (Supplementary Methods).
Power analysis. Power analyses indicated that the current metaanalysis is expected to have at least 41% power to detect very common variants (MAF ≥ 0.25) with odds ratios ≥ 1.10 at P < 5 × 10 -8 and 63% power for P < 1 × 10 -6 ( Supplementary Fig. 11 ). Power at P < 1 × 10 -6 is relevant because only five loci reach that threshold in the current meta-analysis. Power is lower for less-common variants (MAF ≤ 0.05) even with odds ratios ≥ 1.20 at P < 1 × 10 -6 (60% power) and P < 5 × 10 -8 (38% power). For perspective, power computations using the observed distribution of top effects for other large GWAS of polygenic traits suggest that we observed significantly fewer GWS loci for AD than would be expected if the loci had true effect sizes and allele frequencies similar to schizophrenia (expected: 25.4 loci, 95% confidence interval: 21-30) or obesity (expected: 8.9 loci, 95% confidence interval: 6-12), but not fewer than would be expected for effect sizes similar to major depression (Supplementary Methods and Supplementary Table 8 ).
Discussion
To our knowledge, this is the largest GWAS of rigorously defined AD to date, comprising 14,904 AD individuals and 37,944 controls. We identified known loci in ADH1B that differed between EU and AA, as well as previously uncharacterized genetic correlations between AD and psychiatric disorders (for example, schizophrenia), tobacco and cannabis use, and social (for example, socioeconomic deprivation) and behavioral (for example, educational attainment) outcomes. Analyses also revealed a genetic distinction between GWAS results for alcohol consumption and AD. Overview of numbers of individuals with AD (cases) and controls from each cohort in the current analysis, including the number of genetically unrelated individuals. Cohorts are listed by study design and analysis method. Sample sizes are listed after quality control exclusions and stratified by ancestry group. PubMed identifiers (PMID) are listed for previous publications describing each cohort, along with the percentage of male samples and the age range in the cohort. Although larger sample sizes can be amassed by focusing on quantitative measures of consumption, only the upper tail is relevant to AD (as a medical diagnosis), and even that does not capture other aspects of disordered drinking (for example, loss of control, withdrawal) directly. Conversely, cases derived from electronic medical records (for example, International Classification of Diseases (ICD) codes) result in a high rate of false negatives, while self-screening instruments (for example, AUDIT scores) are best suited to analyses of disordered drinking when a sufficiently high threshold or score cutoff is applied to focus on severity. Our study has the advantage of greater diagnostic precision via use of semistructured interviews to diagnose AD systematically in a majority of the constituent studies and therefore greater interpretability in the context of clinically important AD. The GWS SNPs reaffirm the importance of functional variants affecting alcohol metabolism to the risk of AD. The top association in ADH1B, rs1229984, is a missense variant that is amongst the most widely studied in relation to alcohol use, misuse, and Top ten nominally independent variants from the discovery transancestral (trans.; n case = 14,904; n control = 37,944) meta-analysis and the discovery meta-analyses in AA (n case = 3,335; n control = 2,945) and EU (n case = 11,569; n control = 34,999) ancestry cohorts, respectively. Independent variants are identified based on clumping for LD (pairwise r 2 < 0.1) in 1000 Genomes Project Phase 3 data 21 . EU results are clumped using European ancestry reference samples, AA results are clumped using African ancestry reference samples from the American Southwest, and transancestral results are clumped using merged European and African ancestry reference samples. P values and allele frequencies are reported from two-tailed tests of association with AD in fixed-effects meta-analyses weighted by effective sample size. Bold P values indicate GWS after correction for multiple testing within the analysis (P < 5 × 10 -8 ). Odds ratios (OR) and INFO scores are reported from the meta-analyses of the subset of unrelated individuals within each ancestry. Variants are sorted by chromosome (Chr) and base pair (BP) position for genome build hg19, with genes annotated by Ensembl VEP 49 . Allele frequency and OR are given with respect to allele 1 (A1). SNPs included in the transancestral meta-analysis were not conditioned on being analyzed in both the EU and AA analyses. For instance, a SNP of strong effect in one group may not be sufficiently common or well-imputed for analysis in the other ancestral group (for example, rs2066702 is not found in non-African populations but is among the top ten in the transancestral analysis due to strong effects in the AA group). For rs7644567 (denoted with *), the SNP did not pass quality control in a sufficient number of cohorts to meet the minimum sample-size requirement for inclusion in the EU-only analyses-it is only represented among EU cohorts by summary statistics from two Finnish cohorts-but allele frequency, INFO score, and meta-analyzed P values from the Finnish summary statistics are reported since they contribute to the transancestral meta-analysis.
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Nature NeuroscieNce dependence [8] [9] [10] . The resulting amino acid substitution (Arg48His) increases the rate at which alcohol dehydrogenase 1B oxidizes ethanol to acetaldehyde 8 . Studies on Asian populations in which the derived allele is common demonstrated strong protection against the development of AD 8, 9, 13 . In EU and AA, the protective allele is present at much lower frequencies (EU, MAF = 0-4%; AA, MAF < 1%); nevertheless, recent large-scale studies have shown an association between this locus and alcohol consumption and problems at GWS levels in EU with similar effect size [8] [9] [10] . The lead variant in AA cohorts, rs2066702 (Arg370Cys), is another functional missense variant in ADH1B, and it also encodes an enzyme with an increased rate of ethanol oxidation 8 . The allele encoding Cys370 is common in AA, but rare in other populations 8 . Our results clearly show that these two different functional SNPs in ADH1B both affect risk for alcoholism, with their relative importance dependent upon allele frequency in the population studied. There is a suggestion of additional independent effects in the chromosome 4 region, but larger studies will be needed to evaluate this.
The only other locus to reach significance was rs7644567 on chromosome 3, primarily driven by AA cohorts. The locus failed to replicate in two small, independent AA samples, and in the only European cohort with even a modest allele frequency (FINRISK), the effect was in the opposite direction. There have also been discussions about whether the standard GWAS significance threshold should be applied to the more genetically diverse African-ancestry cohorts 22, 23 and about the possibility of confounding from nonlinear relationships between phenotypes and ancestry-informative markers like rs7644567 in admixed samples 24 , all of which increase our skepticism regarding this finding. There is, therefore, insufficient evidence at this time to conclude that rs7644567 is associated with alcohol dependence. Analyses of much larger samples of African ancestry will be needed to resolve this.
Despite limited SNP-level findings, there is significant evidence for polygenic effects of common variants in both EU and AA cohorts. The estimated h , and it is comparable to estimates derived for cigarettes-per-day 25 . Our h 2 g estimate is lower than that of a prior report 7 , likely reflecting a combination of differences in estimation method (genomic relatedness matrix restricted maximum likelihood (GREML) versus LDSR) and greater heterogeneity in ascertainment strategy across samples in the current study (see refs [26] [27] [28] ). The latter is especially relevant in comparing h 2 g from that prior single cohort to our meta-analysis, which included cohorts with a wide range of ages at ascertainment, cultural environments, and ascertainment strategies, including enrichment for other substance use disorders. Similarly to other psychiatric disorders (for example, schizophrenia), a much larger sample size will potentially aid in overcoming across-sample heterogeneity and will capture a greater proportion of genetic variance.
Comparing our GWAS to recent GWAS of alcohol consumption measures suggests that the liability underlying normative patterns of alcohol intake and AD are only partially overlapping. Genome-wide genetic correlations were significantly < 1 with log-scaled alcohol consumption by participants in AlcGen and CHARGE+ Consortia cohorts 16 (r g = 0.695, s.e. = 0.15, one-tailed P = 0.024 for r g < 1) and in the UK Biobank 17 (r g = 0.371, s.e. = 0.092, one-tailed P = 3.2 × 10 -12 for r g < 1). We also observed only partial replication of the eight loci significantly associated with consumption in the UK Biobank, with strongest results from SNPs in the ADH region, including a proxy for rs1229984. In addition, there was no significant correlation with GWAS of log-scaled AUDIT scores in 23andMe participants 18 (r g = 0.076, s.e. = 0.171, two-tailed P = 0.656). Subsequent analyses suggest these estimates are sensitive to sample characteristics, with somewhat higher genetic correlations reported in analysis of alcohol consumption in the full UK Biobank 29 (r g = 0.75) and of AUDIT in combined data from 23andMe participants and UK Biobank 30 (r g = 0.39). Notably, initial UK Biobank data includes a subset of participants recruited for a study of smoking and lung function in the = 14,904 ; n control = 37,944); (b) AA cohorts (n case = 3,335; n control = 2,945); and (c) EU cohorts (n case = 11,569; n control = 34,999). Red reference line indicates the GWS threshold after correction for multiple testing within each analysis (P < 5 × 10 -8 ). Within ancestry, colored points reflect the degree of LD (pairwise r 2 ) to the index variant (purple diamond) in 1000 Genomes Project reference data 21 for individuals of (b) African or (c) European ancestry, respectively. LD structures in the two ancestries differ, so for the transancestral sample (a), LD is not given, indicted by gray points. Two-tailed tests used for all analyses. Chr4, chromosome 4.
Nature NeuroscieNce first analysis 17 , which may have resulted in collider bias 31 and contributed to the initial lower genetic correlation.
One key factor in interpreting the differences between these traits and AD is that the distribution of consumption levels and AUDIT scores can be highly skewed in population samples, with most individuals at the low (nonpathological) end of the spectrum. This effect may be especially pronounced among the older, healthy volunteers of the UK Biobank cohort 32 and in the 23andMe cohort, which is more educated and has higher socioeconomic status than the general US population 18 . We hypothesize that the variants that affect consumption at lower levels may differ substantively from those that affect very high levels of consumption in alcohol dependent individuals, who are also characterized by loss of control over intake 33 . This appears to be the case in studies that used specific cut-offs to ; bold), with nominally significant results for eight additional traits and disorders (P < 0.05; italics) based on two-tailed tests of the estimated genetic correlation with block jackknife standard errors. Error bars indicate 95% confidence intervals; arrows indicate intervals extending above 1 or below -1. Vertical gray reference line corresponds to the null hypothesis of no genetic correlation with AD. Phenotypes are organized by research domain. ADHD, attention deficit-hyperactivity disorder; HDL, high-density lipoprotein; HbA1c, hemoglobin A1c; GGT, gamma-glutamyl transferase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase.
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harmonize AUDIT scores with AD data 30, 34 . The larger of these studies 30 reports that the genetic correlation between AD and AUDIT scores is maximized at an AUDIT cutoff ≥ 20 (with controls defined as those scoring ≤ 4; r g = 0.90). Notably, that study also found that a score reflecting items related to problem drinking (AUDIT-P) resulted in a stronger genetic correlation (r g = 0.64) than a score related to alcohol consumption alone (r g = 0.33). The strong genetic correlation of AD with lower educational attainment and lower socioeconomic status (i.e., higher Townsend deprivation), in contrast to positive genetic correlations of education with consumption 17 and AUDIT scores related to consumption 30 , further underscore this distinction between normative or habitual levels of alcohol intake and diagnosed AD, at least in the respective populations studied.
The current analysis identified robust genetic correlation of AD with a broad variety of psychiatric outcomes. This correlation was strongest for aspects of negative mood, including neuroticism and major depression, as also seen in twin studies 35, 36 and through recent specific molecular evidence for pleiotropy 37, 38 . Taken together with evidence from other recent genomic studies 37 , and with null correlations for other GWAS of alcohol consumption but not for measures of problem drinking (for example, AUDIT-P), these findings suggest that major depression may primarily share genetic liability with alcohol use at pathological levels.
AD was also strongly genetically correlated with poor educational and socioeconomic outcomes and marginally correlated with measures of risk-taking. Nominally significant genetic correlations with delay discounting (i.e., favoring immediate rewards) and risktaking, and the strong genetic correlation of AD with attention deficit-hyperactivity disorder, cigarette smoking, and cannabis use, may similarly reflect a shared genetic factor for risk-taking and reduced impulse control. Common genetic liability to early, risky behaviors is characteristic of both AD 39 and age of first birth
40
. The observed negative genetic correlation with age of first birth is consistent both with risk-taking and with the significant genetic correlations of AD with lower socioeconomic status, as indexed by higher neighborhood Townsend deprivation score and lower educational attainment. Lower socioeconomic status is correlated with both AD 41 and age of first birth 42 , and the current study suggests that shared genetic liabilities may be one potential mechanism for their observed relationship. However, the question of whether these genetic correlations represent causal processes, horizontal pleiotropy, or the impact of unmeasured confounders should be explored in the future 43 . Lower genetic correlations were observed for most biomedical and anthropometric outcomes. Liver enzymes GGT and ALT, once proposed as possible biomarkers for alcohol abuse 44 , showed only nominal evidence for genetic correlation with AD, and neither survived multiple-testing correction. Notably, we did not find any association between AD and body-mass index (BMI). Negative genetic correlations with BMI were previously reported for both alcohol consumption 17 and AUDIT scores 18 , but there is prior evidence that BMI has differing underlying genetic architectures in the context of AD and outside of that context 45 . The negative genetic correlations observed in those studies are consistent with studies of light to moderate drinking, which is also associated with healthier lifestyle behaviors, while heavy and problematic drinking is typically associated with weight gain 46 . This study benefited from precision in diagnostic assessment of AD, known alcohol exposure in a majority of the controls, and careful quality control that excluded overlap of individuals between studies. Despite these strengths, our sample size was insufficient to identify additional GWS loci robustly. Power analyses indicate that additional SNPs associated with AD are likely to have small effect sizes, smaller than schizophrenia 47 and more consistent with more common psychiatric disorders (for example, major depression 48 ). This supports the pressing need for collection of large numbers of well-characterized cases and controls. The differences between our results and the study of AUDIT scores 18 highlight that ascertainment and trait definition are critically important and must be taken into account. Careful study of how screening tools, such as the AUDIT, correlate with genetic liability to AD (as defined by DSM-IV or similar) could substantially boost sample sizes for future AD GWAS. There is also a continued need to characterize the genetic architecture of AD in non-EU populations.
We show a previously unreported genetic distinction between drinking in the pathological range (AD) and habitual drinking that does not cross the threshold into pathology or dependence and does not capture behavioral aspects of disordered drinking. Larger future samples will allow us to uncover additional pleiotropy between pathological and nonpathological alcohol use, as well as between AD and other neuropsychiatric disorders.
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19. Sanchez-Roige, S. et al. Genome-wide association study of delay discounting in 23,217 adult research participants of European ancestry. Nat. Neurosci. 21, 16-18 (2018 Data exclusions Data exclusions were performed based on (a) failure of pre-determined data quality control criteria and (b) planned phenotype exclusions to avoid confounds in defining alcohol dependence cases and controls.
For quality control, individuals were excluded if they were observed to have low genotyping quality (i.e. high missingness rates), excess heterozygosity (an indicator of possible sample contamination or other technical artifacts), or if they deviated from reported family pedigree structures (i.e. excessive mendelian error rates, discordance between genetically-inferred and reported sex, cryptic genetic relatedness to unrelated individuals, or lack of expected genetic relatedness to members of the same pedigree). Observed outliers of genetic ancestry, as determined by principal components analysis, were also excluded in order to avoid the known risk of population stratification in genome-wide studies including such individuals. Ancestries other than African or European were excluded due to insufficient sample size for a meaningful analysis in the currently available data.
For phenotype-based exclusions, we omit individuals lacking phenotype information for alcohol dependence, individuals who report never being exposed to alcohol, and individuals meeting criteria for alcohol abuse (i.e. qualifying neither as alcohol dependence cases or healthy controls). Cohorts with other exclusion criteria as part of their original study recruitment are detailed in the Supplementary Information.
The metrics used as exclusion criteria were established prior to the analyses, but some thresholds used for exclusion (e.g. threshold from principal components analysis to define ancestry strata) were evaluated during the QC process. All of the above exclusions were made in accordance with the planned study protocol, and are detailed in the manuscript.
Replication
The primary genome-wide significant locus identified in the current study (i.e. the ADH1B locus) is itself a replication of previous studies of alcohol dependence (see manuscript for references).
For the novel genome-wide significant locus on chromosome 3, we present more targeted replication analysis from 3 additional cohorts of African and Finnish ancestries relevant to the putative signal. As described in the manuscript, replication was not found. We rely on this lack of replication to conclude that there is not sufficient evidence for an effect of the chr. 3 locus, with the result observed in the discovery sample potentially reflecting confounding from ancestry or an increased multiple testing burden. We also evaluate the consistency of effects in this locus between European and African ancestry cohorts and across study designs as a form of internal replication. These tests find very little evidence of any heterogeneity, indicating that the reported results have generally consistent evidence across ancestry and study design. Polygenic risk score analyses also provide generalizability of the overall results in both European and African ancestry cohorts. In all instances, polygenic risk scores derived from effect sizes in this study successfully predicted alcohol-related phenotypes in other studies as expected. The only instance of poor prediction was that effect sizes from the EA discovery GWAS in this study only weakly predicted alcohol dependence in an independent AA sample (COGA AAfGWAS), which is consistent with prior observations about cross-population polygenic prediction.
The strong sample size requirements of the secondary analyses (most notably LD score regression analyses of heritability and genetic correlation to other traits) and dependence on LD reference panels limits options for direct replication of those findings. We instead focus on comparisons to existing GWAS of other alcohol-related phenotypes to get potential insight into how genome-wide results appear to generalize between these phenotypes in different study populations. The compelling findings from those comparisons are a key result for the current analysis and are discussed at length in the manuscript.
Randomization Randomization of experimental groups was not applicable to this study. The experimental conditions are determined by each individual's genetics, which are fixed at conception. Conceptually this reflects a randomization of the alleles inherited from each individual's parents (i.e. mendelian randomization), but it does not involve randomization of experimental conditions by the researchers in a classical sense. Our study assess the observed association between that natural randomization of genotype and the ascertained phenotype of alcohol dependence.
Blinding
Blinding is not relevant to the current study. Samples were not allocated to different conditions by the researches, and the phenotype ascertainment process is fully separate from the genotyping process.
Reporting for specific materials, systems and methods 
Human research participants
Policy information about studies involving human research participants
Population characteristics
The current study encompasses 14,904 cases and 37,944 controls from 28 cohorts in the primary analysis (after quality control), with an additional 2,997 cases and 25,318 controls from 3 replication cohorts and 9,629 individuals in 2 other cohorts used for
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polygenic risk score analysis. Details on each cohort are provided in the manuscript, with summary descriptives in Table 1 and full descriptions in the Supplementary Information.
Briefly, included participants represent a mix of ascertainment schemes across cohorts, including both population-based collections and ascertained research cohorts. These include studies of genetically unrelated cases and controls, as well as familybased studies ranging from sibling pairs to extended pedigrees ascertained for enrichment of substance abuse. Overall, the participants include roughly equal numbers of males and females, with ages fully distributed across the lifespan for adults. Participants are from North America, Europe, and Australia and are of European or African ancestry (confirmed in genetic data), with African ancestry individuals predominantly reflecting African-American admixture.
Genome-wide genotype data has been collected for all participants. Most individuals in the primary analysis were analyzed using the individual level genotype data, but a subset (N=9,929 from 5 cohorts) are only represented in summary statistics from their respective cohorts. The 3 replication cohorts are also only analyzed through contributed summary statistics.
Phenotyping criteria vary by cohort (full descriptions in the manuscript supplement), but for most cohorts a standardized measure such as the Semi-Structured Assessment for the Genetics of Alcoholism (SSAGA) or the Composite International Diagnostic Interview (CIDI) has been administered to ascertain lifetime alcohol dependence status in accordance with DSM-IV diagnostic guidelines. Current treatment data has not been collected for all participants, but is not critical to the current research question of genetic associations with lifetime dependence diagnosis.
Recruitment
Participants were recruited separately for each cohort according to their respective study design. Descriptions of the design for each cohort can be found in the Supplementary Information, along with references to previous publications containing complete details.
Overall, the cohorts represent a mix of population-based cohorts without targeted ascertainment (e.g. birth cohorts from a specified region), cohorts recruited for studies of alcohol dependence (e.g. families of probands from inpatient or outpatient treatment facilities), or cohorts originally recruited for studies of other substance dependence (e.g. cocaine or nicotine) or other phenotypes where measures of alcohol dependence were included in phenotyping (e.g. schizophrenia, high-risk populations involved in the criminal justice system, or pharmacogenetics studies).
These recruitment strategies could yield biases in the results for a given cohort, but the mix of recruitment strategies used across the cohorts is unlikely to produces consistent biases across the current analysis. Instead, any different biases resulting from the variety of recruitment strategies and study designs would be more likely to manifest as heterogeneity or noise in results across the cohorts, potentially reducing power.
